Tempest Therapeutics, Inc. (TPST) Operating cash flow 2016–2025
Tempest Therapeutics, Inc. (TPST) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$26.8MFY2025 · since FY2016: -$61.7M → -$26.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$26.8M | +18.8% |
| FY2024 | -$33.0M | -20.7% |
| FY2023 | -$27.4M | +12.0% |
| FY2022 | -$31.1M | -19.7% |
| FY2021 | -$26.0M | -36.5% |
| FY2020 | -$19.0M | +53.9% |
| FY2019 | -$41.2M | -74.3% |
| FY2018 | -$23.6M | -16.3% |
| FY2017 | -$20.3M | +67.1% |
| FY2016 | -$61.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TPST financial trends
TPST RevenueTPST Net incomeTPST Net marginTPST Gross profitTPST Gross marginTPST Operating incomeTPST Operating marginTPST Free cash flowTPST Capital expendituresTPST Return on equityTPST Stock buybacksTPST Dividends paidTPST Total assetsTPST Total liabilitiesTPST Shareholders’ equityTPST overview →